Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Mar 7, 2008; 14(9): 1378-1382
Published online Mar 7, 2008. doi: 10.3748/wjg.14.1378
Published online Mar 7, 2008. doi: 10.3748/wjg.14.1378
Table 1 Cell cycle analysis showing MK615 treatment increased the cell population in G2-M phase in all three pancreatic cancer cell lines.
| MK615 | G0-G1 | S | G2-M | |
| PANC1 | (-) | 68.1 | 24.2 | 7.8 |
| (+) | 71.6 | 15.4 | 13.0 | |
| PK1 | (-) | 55.9 | 42.2 | 1.8 |
| (+) | 68.8 | 26.0 | 5.2 | |
| PK45H | (-) | 56.0 | 21.1 | 22.9 |
| (+) | 59.0 | 11.7 | 29.3 |
- Citation: Okada T, Sawada T, Osawa T, Adachi M, Kubota K. MK615 inhibits pancreatic cancer cell growth by dual inhibition of Aurora A and B kinases. World J Gastroenterol 2008; 14(9): 1378-1382
- URL: https://www.wjgnet.com/1007-9327/full/v14/i9/1378.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.1378